Anticancer drug company: PlasmaTech Biopharmaceuticals (PTBI)

PlasmaTech Biopharmaceuticals, Inc. (NASDAQ:PTBI), formerly known as Access Pharmaceuticals, Inc., was renamed PlasmaTech in October 2014. It has 7 full-time employees and is headquartered in Dallas, Texas. It is a cancer company A biopharmaceutical company engaged in protein biotherapy research and tumor treatment drug development.

PlasmaTech Biopharmaceuticals

PlasmaTech Biopharmaceuticals (PTBI) company introduction:

PTBI’s currently marketed products include:

  • MuGard-treatment of oral mucositis;
  • ProctiGard-treatment of radiation proctitis (a common side effect of radiation therapy in the pelvic area);
  • CobOral-mediating oral administration technology (using the natural vitamin B12 transport system in the human intestine);
  • CobaCyte-a targeted delivery technology that can target tumor cells during cancer treatment.

PlasmaTech Biopharmaceuticals (PTBI) investment reference:

PTBI was about the same as ADRO , VLTC , GENE (also told similar stories, the stock price rose from 0.5 US dollars to 11 US dollars within a month, an increase of 2200%), etc., without any surprises, 2015-05-05 market news, Soros Has bought 5.17% of PTBI’s shares. The news pushed the stock up by more than 170% and closed up by 108.7%. It was the star stock of the day. This is the charm of small biotech stocks with low market capitalization.

PTBI official website:

PTBI Chinese introduction:

Notify of
Inline Feedbacks
View all Intels

US military stocks: GenCorp (GY)

[October 2020] Summary of account opening offers for Hong Kong and U.S. stock brokers-Weiniu Futu Tiger Xueyinghua Shengyouxin Securities